PDL BioPharma, Inc. PDLIV

PDLIV Company Overview

PDL BioPharma, Inc. (traded historically under Nasdaq ticker PDLI and later associated with the OTC symbol PDLIV during liquidation-related trading activity) was a U.S.-based specialty finance and biotechnology-focused company that evolved from a biotechnology research enterprise into a royalty monetization and healthcare investment business. The company became widely known for managing and licensing intellectual property tied to humanized monoclonal antibody technologies, particularly through royalty streams connected to antibody therapeutics developed by major pharmaceutical companies. Over time, PDL shifted away from direct drug development and increasingly focused on acquiring healthcare-related royalty assets, debt investments, and specialty pharmaceutical holdings.

The company’s primary revenue drivers historically included royalty payments from patented antibody technologies, interest income from structured finance arrangements, and returns from healthcare asset acquisitions. PDL operated in sectors including biotechnology licensing, specialty pharmaceuticals, and healthcare finance. Its strategic positioning was tied to its intellectual property portfolio and its ability to generate cash flow from long-duration licensing agreements and structured investments. Public filings and historical investor disclosures indicate that the company gradually transitioned into a liquidation and asset monetization process after the expiration of key royalty-generating patents and the reduction of recurring licensing revenue.